+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 50Years
All Genders
Healthy Volunteers
ID06827470

Phase 12 Study to Find the Best and Safe Dose of Intranasal Bordetella Pertussis J820 in Healthy Adults 18 to 50 Years Old to Cause Mild Whooping Cough Infection

Led by Dalhousie University · Updated on 2025-12-04

60

Participants Needed

1

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are establishing a controlled human infection model to study pertactin-deficient Bordetella pertussis, the bacteria that causes whooping cough. The study aims to represent currently circulating strains in North America, considering vaccination and infection history. This phase 12 clinical trial is open-label and focuses on determining a safe and effective dose for intranasal administration in healthy adults aged 18 to 50. Participants will receive different escalating doses of Bordetella pertussis J820 administered intranasally in each nostril on the first day of the study. Five dose groups range from 105 to 109 bacteria to identify the optimal dose that causes mild symptoms and detectable infection. There is no placebo group, as all participants receive the experimental intervention. During the study, participants will be monitored closely from day 1 through day 29, with some secondary measures extending up to day 181. Researchers will collect nasal samples to detect bacteria and assess symptoms. Safety and response to the bacterial challenge will be evaluated through clinical exams and laboratory tests. Participants must complete diary cards and attend follow-up visits, with the total participation lasting several months.

CONDITIONS

Brief Title

Establishing a Controlled Human Infection Model of Pertactin-deficient Bordetella Pertussis

Research Team

N

Nick Bartlett

H

Hannah Munday

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here